Company intelligence / Profile preview

Unicyte

Ownership: Private
Development stage: Preclinical

Overview

Unicyte is developing proprietary stem cell and extracellular vesicle-based therapies targeting kidney, liver, metabolic, and oncological diseases, currently at phase 2 clinical stage for some programs, with preclinical and translational data supporting regenerative efficacy in diabetes, nephropathy, and oncology.

Therapeutic areas: EndocrinologyNephrologyGastroenterologyOncology
Modalities: Stem cell therapyExosome-based therapyCell therapy
Industry: Biotech

Drug pipeline

2 assets

HLSC-001

Unknown

1 more asset in the full pipeline.

Request access →

Partnerships

Fresenius Medical CareUniversity of Turin

Beyond the preview

Go deeper on Unicyte.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Unicyte.

Explore the full profile